Unlock the path to regulatory success with Pharmaron’s comprehensive safety assessment services, designed to meet the specific needs of each drug candidate.
With more than 2000 safety studies completed and broad expertise across small molecules, biologics, and advanced modalities such as cell and gene therapies, Pharmaron is a trusted partner for preclinical and IND-enabling studies.
Key aspects of Pharmaron’s safety assessment services include:
- End-to-end capabilities: Pharmaron provides a full range of safety evaluation services, including acute and chronic toxicity studies, developmental and reproductive toxicology, genotoxicity, and environmental risk assessments.
- Specialized expertise: Services include safety assessment for ocular and dermal drugs, medical devices, and emerging therapeutic areas, supported by advanced imaging and pathology techniques.
- Regulatory excellence: Pharmaron operates under accreditations from global regulatory bodies, including the FDA, OECD, EMA, NMPA, and MHRA, delivering high-quality, compliant data to support successful regulatory submissions.
With AAALAC-accredited facilities and integrated capabilities from discovery through post-marketing, Pharmaron simplifies the safety assessment process and provides consistent, expert support at every development stage.
Download your free copy of the eBook to learn more about how Pharmaron’s tailored solutions can help advance drug development programs.
About Pharmaron
Pharmaron is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 17,000 employees, and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.